Medical personnel worldwide are developing new human antigen vaccines, including various types of cancer preventive and therapeutic. Click for details: The light of hope to end cancer-2019 global inventory of the latest cancer vaccine! (Covering six major cancers).
Immune cells (pink and red) attack tuberculum cells (blue) that produce new antigens (blue and orange). Vaccines can help train immune cells to recognize new antigens.
Recently, scientists have developed a vaccine that can destroy the mutant cells made by Lynch syndrome (Lynch) DNA in mice, and may one day prevent people with the genetic disease Lynch syndrome from developing colorectal cancer.
De studiis referunt in Lynch syndrome (Lynch) mus exemplar, quod vaccination cum paucis in quatuor potest tumor antigens producendum ad gene-specifica responsionis redigendum alvi stercora digeruntur, et salvos meliorem.
According to the data provided by the recent AACR annual meeting, this pre-human study shows that it is possible to develop a vaccine to prevent cancer in patients with Lynch syndrome.
Carcinogenic Lynch-geneticae morbo syndrome
Lynch syndrome, commonly referred to as hereditary nonpolyposis colorectal cancer (HNPCC), is an inherited disease that may be caused by mutations in genes inherited from parents to children and increases the risk of many types of cancer , Including colon cancer, endometrial cancer, ovarian cancer, gastric cancer, small intestine cancer, pancreatic cancer, kidney cancer, brain cancer and cholangiocarcinoma. Especially colonia cancer and rectal cancer. People with Lynch syndrome have a 70% to 80% risk of colorectal cancer.
In Iunctus Civitas, fere 140,000 novum casibus diagnosed quolibet anno autem colorectal cancer. Ad III% V% de carcinomata horum quae fecit per Lynch syndrome.
A vaccine ne Lynch syndrome
At present, patients with Lynch syndrome can only avoid colorectal cancer through frequent screening and prevention. Low-dose aspirin has also been shown in clinical trials to reduce the risk of colorectal cancer.
Potest providere vaccina et alia potentia est magis efficens via ut prohibere ad progressionem cancer.
Nuper, Inquisitores enim de vaccina sumptus magni momenti gradum evolutionis in ne cancer de summus periculo morbo, Lynch syndrome (Lynch).
Steven Cornkin scientists ducitur, MD, de Cornell Weill, nuntiavit eventus cancer ne NCI-funded a Vaccinum probat recens American Association ad Cancrum ab anno testimonii Research. Cum unvaccinated mus id impedirent vaccini colorectal incrementum tumores aureos in Lynch syndrome quaeque muris salutem consequantur.
Et principalis investigator, Dr Lipkin et vitium Praesidem, Rei Medicae apud Department of research in New York, consilia neoantigens ut identify communis, quod est in fieri mane, cum aegris tumores in colorectal Lynch syndrome. A project erat funded per National Cancri Instituti (NCI) Cancri per "lunam Explorationis Program" madicament-Oncology transmutatio network.
Dr. Lipkin iudiciis humanis dictum est quod si de vaccina cancer ne quid proficiant est, ut aliquot annos determinare utrum sit effective.
In eodem tempore, in quadrigis melius intellegere quam sit usura mus exempla monstrabit, ut in Vaccinum et quomodo opera a growing cancer cellulis ad resistere effectus.
Inventio est communis syndrome cancer mutationes in Lynch
Causa est Lynch syndrome per geneticae mutations hereditarium, quod fieri potest, ne ad instaurationem et supellectilem erroresque mortalium inter DNA cellula divisio est. Tales errores dicuntur mismatch repair defectus.
Non haec amo usura a DNA spell checker. Nec defensioni DNA tandem erroribus variis coacervabunt cellulis et cancer.
DNA in summa repetens DNA fragmenta dicitur BLE mismatches maxime obnoxia. Multiplices mutationes eventually mismatch reparationibus in secretiori parte natium: et in his BLE. Microsatellite hoc statu dicitur instabilitas.
Volubiles novas Microsatellite tumores et servo, novi antigenos quae corpora externa corporis et felis feugiat impetum faciunt cellas servo.
Qua de causa, in investigatores invenitur magis notitia. Usu formatae sunt in populo cum saepe Lynch syndrome have idem microsatellite mutationes taceam, quam tantam in LX% ad LXXX% of populus cum colorectal cancer, quod habet defectum reparacionis mismatch. Non erit propria microsatellite mutations in gene TGFBR60.
Et cancer progressionem ipsum de vaccina
In MMXI, Inquisitores a National Cancri ipsum Center Heidelbergae in Germania, novum coepit orci iudiciis antigen de vaccina in provectus populus cum colorectal cancer. His aegris habent excelsum microsatellite instabilitas.
Primum enim a colorectal XXXII scientists searched DNA in secretiori parte natium Lynch syndrome mus identified quod exemplar commune mutationes XIII.
In investigatores participatur tum usus an algorithm esse venturam dicunt, quod mutationes novas antigens, postremo identified X speciei. X in iis instillatur cum nova antigenos mures utitur quattuor fortis immune responsum.
Hi quatuor antigenos componantur ad vaccini mus. Et deprehendi usum mus exemplum de vaccina et adjuvants in secretiori parte natium et per patientiam sustentatur Lynch syndrome potest reducere progressionem colorectal salvos.
"Haec est primum de vaccina cancer immunopreventive novis utens antigens, quae formatae sint ut in DNA mismatch repair supplendo defectus predictos," dicit Dr. Umar.
Deinde debet determinari Inquisitores sive meliorem combining Vaccinum cum aliis treatments potest virtuosius inveniatur. Eg Naprosyn, plerumque adsuesco assuesco per analgesic, ut ostensum est superior ad aspirin aut in potestatem redigere in secretiori parte natium mus colorectal progressionem exempla monstrabit. Maiorem efficaciam vaccini naproxen videtur. Tractata habebat mures aureos et similitudines murium, vaccinated Vaccinum solum diutius quam vixit plus naproxen vaccinated vel plus aspirin. In immune cellulis in coetus naproxen Vaccinum plus poterant iudicare, cognitione magis novo quam mures in Vaccinum solum Vaccinum antigen vel Vaccinum aspirin plus group.
Conclusio
Lynch apud syndrome ut candidati ad cancer ne vaccina populus meus, developed si.
Current NCCN guidelines commendant microsatellitem instabilitatem probandi pro hominibus cum cancro colorectali et cancro endometriali. Si tumor aegri experimentum positivum est pro inconstantia microsatellite, suadetur ut probetur syndrome Lynch. Si diagnoscatur sicut syndrome Lynch, commendatur ad experimentum primi gradus propinqui patientis ne fiat.
Adhortatio fit ut summus periculo coetus Picea genes geneticae possunt ad opposita texit pro parte corporis. Pro specifica typus of protegendo, consule obsecro Global oncologist Network Imperatoris Medici (400-666-7998) et eligere fundatur super familiae personalis historia et periculo factores:
- Picea gene deprehensionem cancer geneticae (Genes summa CXXXIX)
- CXXXIX Covers genes in genere humano genome sunt ad cancer, in quibus XX LXX genera cancer et cancer-related rationes geneticae syndromes
- Picea gene geneticae tumor test (Genes commune XXIII):
- Periculum cancer de summus XIV et VIII species involves species est communis geneticae syndromes
- Picea gene test cancer geneticae (XVIII de mulieribus genes)
- Involves genera III summus periculo secretiori parte natium et feminam V geneticae typus of related syndromes
- Picea gene deprehensionem cancer geneticae (XVII genes in digestivorum tractus)
- V tractus parte corporis digestivorum involves genera et VIII species summus periculo related geneticae syndromes
- Pectus cancer + breast cancer: BRCA1 / 2 gene
- Colorectal cancer, XVII Genes
- Omnes tumores: XLIV genes
